Lead Product(s): Irofulven
Therapeutic Area: Oncology Product Name: LP-100
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Lantern Pharma
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 26, 2021
Irofulven is a well-studied small molecule that causes bulky single strand DNA adducts that cause DNA damage in cancer cells, which can only be repaired by the transcription coupled nucleotide excision repair (TC-NER) pathway.